The pediatric neurologist at Nationwide Children's Hospital talked about current gaps and potential treatment approvals in epilepsy care for 2023. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
“Trying to expand people's knowledge and use of quality improvement methodology is going to be something I'm also excited to help participate in for 2023 and beyond.”
Epilepsy care has advanced more with the use of healthcare systems to keep track of patients and their health status; although, gaps still remain with documenting patient data. To effectively prescribe patients' treatments, having a more effective method of patient documentation and sharing it with other centers has potential for more personalized treatments, and thus, lead to improved and higher quality care for patients with epilepsy.
There are several exciting ongoing trials that could lead to FDA approvals in 2023, says Anup Patel, MD. Additionally, he adds there is progress with certain types of gene therapies outside of epilepsy in other neurological conditions such as spinal muscular atrophy and Duchenne muscular dystrophy.
In a recent interview with NeurologyLive®, Patel, pediatric neurologist at Nationwide Children's Hospital, sat down to talk about the current gaps in epilepsy care. Patel, professor of clinical pediatrics and neurology at Nationwide Children's Hospital and at The Ohio State University College of Medicine, also discussed what he is looking forward to in the coming months with treatment approvals and ongoing clinical trials.